Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: |
PiperTaz Sandoz |
Active Ingredients: |
Piperacillin monohydrate 4.198g equivalent to piperacillin sodium 4.2531g equivalent to piperacillin 4.0g Tazobactam 0.5g equivalent to tazobactam sodium 0.54733g |
Dosage Form: |
Powder for injection |
New Zealand Sponsor: |
Novartis New Zealand Limited |
Manufacturer: |
Sandoz GmbH, Kundl, Austria |
Note: This consent is given subject to the following conditions: – Provisional consent is to be granted for 1 year to address an urgent shortage in the market. – The medicine may only be marketed or distributed when no other comparable pipercillin/tazobactam medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet sole tender obligations. |
|
Also note: This consent is valid for one year from the date of publication of this notice. |
Dated this 5th day of August 2019.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).